Acadian Asset Management
CGTX icon

Acadian Asset Management’s Cognition Therapeutics CGTX Stock Holding History

Acadian Asset Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-701,940
Closed -$216K – 1844
2025
Q2 		$216K Sell
701,940
-305,646
-30% -$103K ﹤0.01% 1296
2025
Q1 		$422K Buy
1,007,586
+897,353
+814% +$527K ﹤0.01% 1112
2024
Q4 		$76K Sell
110,233
-30,710
-22% -$15.2K ﹤0.01% 1400
2024
Q3 		$64K Buy
+140,943
New +$145K ﹤0.01% 1736
2024
Q2 		– Sell
-12,691
Closed -$23K – 1766
2024
Q1 		$23K Buy
+12,691
New +$26.2K ﹤0.01% 1471

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Acadian Asset Management's CGTX Position: Q3 2025 in Review

Acadian Asset Management sold out of Cognition Therapeutics (CGTX) in Q3 2025, closing a stake of 701,940 shares — an estimated $216K sold.

Acadian Asset Management first reported a position in CGTX in Q1 2024 and held it in 5 quarters. The position peaked at $422K in Q1 2025. 69 funds tracked by Wall St. Rank hold CGTX as of Q3 2025.

  • Acadian Asset Management reported no remaining Cognition Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Acadian Asset Management sold 701,940 Cognition Therapeutics shares in Q3 2025, an estimated $216K.
  • Acadian Asset Management first reported a position in Cognition Therapeutics in Q1 2024 and held it in 5 quarters.
  • Acadian Asset Management's Cognition Therapeutics position peaked at $422K in Q1 2025.
  • 69 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2025.

Based on Acadian Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.